CTOs on the Move

Joule Unlimited

www.jouleunlimited.com

 
Joule has pioneered a CO2-to-fuel production platform, effectively reversing combustion through the use of solar energy. Free of feedstock constraints and complex processing, this platform can achieve unrivaled scalability, volumes and costs without the use of any agricultural land, fresh water or crops. Unlike products derived with complexity from petroleum or biomass, Joule Sunflow® products are produced in a direct, continuous process from abundant resources. The novel CO2-to-liquids conversion requires only sunlight, non-potable water and engineered bacteria that function as living catalysts to produce specific products, including ethanol and hydrocarbon fuels that are inherently compatible with existing infrastructure. Joule’s highly efficient process ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Funding

Joule Unlimited raised $40M on 05/11/2015

Similar Companies

Inhibitex

Inhibitex, Inc. is a Alpharetta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Remix Therapeutics

Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways.

Genentech

Genentech, Inc., is a biotechnology corporation which became a subsidiary of Roche in 2009.

National Institutes of Health

The National Institutes of Health (NIH) is the largest biomedical research agency in the world, conducting research in its own laboratories, supporting the research of non-Federal scientists in universities, medical schools, hospitals, and research ins...

Lyndra

Lyndra Therapeutics is pioneering the first-ever oral, ultra-long-acting, sustained release therapies, which have the potential to fundamentally change the way people take medicine by enabling patients to take a pill once a week rather than daily. The Company`s breakthrough Extended-Release Oral Capsule is designed to provide consistent drug levels for an entire week or as long as a month, from one, normal-sized capsule – something no oral therapy has ever achieved before. Lyndra`s robust pipeline is made up of therapies with established and well-known safety profiles across a number of disease areas in which non-adherence is known to be a significant driver of outcomes, including schizophrenia and other central nervous system diseases, diabetes, cardiovascular disease and opioid abuse disorder, among others. The Company is also committed to advancing its platform across new chemical entities and a variety of critical global and public health opportunities alongside partners such as the Bill & Melinda Gates Foundation and the NIH.